Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes

Patrick J. O’Connor, MD, MPH, MA1
Gabriela Vazquez-Benitez, PhD1
Julie A. Schmittidil, PhD2
Emily D. Parker, MPH, PhD1
Nicole K. Trower, BS3
Jay R. Desai, MPH1
Karen L. Margolis, MD, MPH1
David J. Magid, MD, MPH3

OBJECTIVE—To assess the impact of early hypertension (HT) control on occurrence of subsequent major cardiovascular events in those with diabetes and recent-onset HT.

RESEARCH DESIGN AND METHODS—Study subjects were 15,665 adults with diabetes but no diagnosed coronary or cerebrovascular disease at baseline who met standard criteria for new-onset HT. Poisson regression models assessed whether adequate blood pressure control within 1 year of HT onset predicts subsequent occurrence of major cardiovascular events with and without adjustment for baseline Framingham Risk Score (FRS) and other covariates.

RESULTS—Mean age was 51.5 years, and mean blood pressure at HT onset was 136.8/80.8 mmHg. In the year after HT onset, mean blood pressure decreased to 131.4/78.0 mmHg and was <130/80 mmHg in 32.9% of subjects and <140/90 mmHg in 80.2%. Over a mean follow-up of 3.2 years, age-adjusted rates of major cardiovascular events in those with mean 1-year blood pressure measurements of <130/80, 130–139/80–89, and ≥140/90 mmHg were 5.10, 4.27, and 6.94 events/1,000 person-years, respectively (P = 0.004). In FRS-adjusted models, rates of major cardiovascular events were significantly higher in those with mean blood pressure ≥140/90 mmHg in the first year after HT onset (rate ratio 1.30 [95% CI 1.01–1.69]; P = 0.04).

CONCLUSIONS—Failure to adequately control BP within 1 year of HT onset significantly increased the likelihood of major cardiovascular events within 3 years. Prompt control of new-onset HT in patients with diabetes may provide important short-term clinical benefits.

Diabetes Care 36:322–327, 2013

The impact of blood pressure reduction on cardiovascular outcomes in patients with type 2 diabetes remains an important clinical and research topic. The UK Prospective Diabetes Study (UKPDS) addressed blood pressure control in patients recently given a diagnosis of diabetes and showed that better blood pressure control reduced the likelihood of cardiovascular events, with an achieved systolic blood pressure (SBP) of 144 mmHg in the intensive arm versus 154 mmHg in the usual-care arm (1,2).

However, several important clinical questions related to treatment of hypertension (HT) in patients with diabetes remain unanswered and are addressed in this report (3–11). First, does early control of HT in patients with diabetes reduce the subsequent occurrence of major cardiovascular events? Second, how long does it take for patients with diabetes and new-onset HT to benefit from lowering of elevated blood pressure? Third, are the putative benefits of early blood pressure control similar in all diabetic patients or do they vary by demographics, baseline cardiovascular risk, or the presence of microvascular complications at HT onset?

Results of these analyses may help providers who make clinical recommendations for the management of blood pressure in patients with type 2 diabetes. This study is especially timely because of the currently active evaluation of blood pressure treatment benefits in type 2 diabetes based on the results of the ACCORD and ADVANCE studies (12,13).

RESEARCH DESIGN AND METHODS

Hypotheses

We hypothesized that blood pressure control in the first year after HT onset would significantly reduce the occurrence of major cardiovascular events (e.g., stroke, myocardial infarction) in a relatively short time. We further hypothesized that such benefits would vary by level of baseline cardiovascular disease (CVD) risk, the presence of microvascular complications of diabetes at HT onset, and the degree of blood pressure control during the first year after HT onset.

Study design and data sources

This retrospective cohort analysis is derived from the Cardiovascular Hypertension Registry of the Cardiovascular Research Network and includes data on all patients identified with HT between 1 January 2003 and 31 December 2009 at one of three integrated health care delivery systems: HealthPartners, Kaiser Permanente Colorado, and Kaiser Permanente Northern California. Blood pressure readings were most often recorded by nursing staff, who were trained at all three sites in standardized measurement of blood pressure, or by primary care physicians. During the study, nearly all measurements of blood pressure were performed manually with aneroid sphygmomanometers rather than digital devices after patients were seated for 5 min in the exam room. Blood pressure readings obtained during emergency department visits, urgent care visits, and

From 1HealthPartners Research Foundation, Minneapolis, Minnesota; 2Kaiser Permanente Northern California, Oakland, California; and 3Kaiser Permanente Colorado, Denver, Colorado.

Corresponding author: Patrick J. O’Connor, patrick.j.oconnor@healthpartners.com.

Received 9 February 2012 and accepted 16 July 2012.

DOI: 10.2337/dc12-0284

The authors of this report are responsible for its content. Statements in the report should not be construed as endorsed by the AHRQ or the DHHS.

This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dci12-0284/-/DC1.

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
hospital admissions were excluded from consideration because they may be influenced by acute conditions and be either higher or lower than blood pressure readings obtained at office visits. The structure of the Cardiovascular Hypertension Registry has previously been described (14,15).

Data collected for the Cardiovascular Hypertension Registry and used in this analysis were extracted from electronic health record (EHR) databases. These included age, sex, race/ethnicity, all ambulatory SBP and diastolic blood pressure (DBP) values, smoking status, height, weight, A1C levels, lipid values, medications (all HT and glucose-control and lipid-control medications), number of primary care and subspecialty care visits per year, and procedure and diagnosis codes related to stroke or myocardial infarction. All three study sites use the EpicCare (Epic Systems, Verona, WI) EHR, and data were extracted from Clarity databases using information system software. Claims databases were also reviewed to ensure complete ascertainment of cardiovascular events because events that occur at hospitals outside the usual care-delivery system may not appear in the EHR but can be identified using claims data.

To confirm that the algorithms designed to identify hypertensive patients were valid and that the analytic data accurately reflected the source data, trained nurse or physician chart auditors conducted a chart review of 450 randomly selected charts (150 from each site). We confirmed that HT onset had, in fact, been documented on the date assigned by the algorithm in 96% of cases and that agreement on blood pressure values between the analytic database and chart records was 98%.

**Study subjects and date of HT onset**

Study subjects in the Cardiovascular Hypertension Registry had to meet all of these additional criteria to be included in the analyses reported here: 1) meet the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) criteria for HT based on two consecutive elevated office blood pressure readings (with SBP ≥130 mmHg, DBP ≥80 mmHg, or both) between 1 January 2003 and 31 December 2009, with at least one calendar year of antecedent data that included no evidence of HT; 2) be age 30–74 years on date of HT onset; 3) meet the study definition of diabetes on or before HT onset, or 4) have no evidence of diagnosed cardiovascular comorbid conditions (ICD-9 410–414, 427, 428, 430–436, and 440–443) before HT onset.

We excluded all patients with a diagnosis code for HT or a filled prescription for any blood pressure–lowering medication (even if purportedly given for a different clinical condition) in the year before the date of entry into the Cardiovascular Hypertension Registry because these subjects could not be considered to have new-onset HT. Subjects who had <1 year of follow-up after HT onset were also excluded. Remaining study subjects were then assigned a date of HT onset, defined as the date of their entry into the Cardiovascular Hypertension Registry. In addition, to be included in the analysis, subjects must have had at least two blood pressure readings within 1 year of HT onset to enable classification of blood pressure control status.

**Variable definitions**

**Diabetes status.** Subjects were classified as having diabetes if, in the year before HT onset, they had 1) either one or more inpatient or two or more outpatient ICD-9 codes for diabetes (codes 250.xx), 2) a filled prescription for a diabetes-specific medication, or 3) two or more fasting glucose values ≥126 mg/dL or one or more A1C values ≥7% (16). Subjects whose filled prescription was for either metformin or a thiazolidinediones were required to also have at least one inpatient or outpatient diabetes diagnosis code. Those with diagnosis codes for gestational diabetes mellitus in the year before or after HT onset were excluded from the analysis. The presence of microvascular diabetes complications at baseline was quantified using the Diabetes Complications Severity Index (17).

**Blood pressure control status in the year after HT onset.** The mean of office SBP and DBP in the year after HT onset was used to classify subjects according to blood pressure status. Study subjects were classified into one of three categories: 1) mean SBP <130 mmHg and mean DBP <80 mmHg, 2) mean SBP ≥140 mmHg or mean DBP ≥90 mmHg, or 3) all other. Two or more blood pressure measures in the year were required to calculate blood pressure control status.

**Baseline cardiovascular risk.** We elected to use the 10-year Framingham Risk Score (FRS) to quantify baseline cardiovascular risk because the model is well established in the literature; is based on U.S. data; has recently been updated to allow separate estimation of CVD, coronary heart disease, stroke, and congestive heart failure risk; and does not require patient-reported data. We used the version of the FRS that assesses risk of 10-year CVD, including both heart attacks and strokes, based on age, sex, current smoking status, SBP, antihypertension medication treatment, total cholesterol, HDL cholesterol, and diabetes status, as described by D’Agostino et al. (17) Age range in the current study was limited to the age range of 30–74 years used by FRS. Patients with missing values used to construct the FRS were excluded from analysis. More detailed variable definitions are included in Supplementary.
RESULTS

Supplementary Fig. 2 shows inclusion and exclusion of study subjects as a flowchart. From 2003 to 2009, we identified 21,705 subjects with HT onset, of whom 18,842 were ages 30–74 years and had no cardiovascular comorbid condition and, therefore, were eligible for inclusion. Subjects were

| Characteristic                              | <130/80 mmHg | 130–139/80–89 mmHg | ≥140/90 mmHg | p** |
|---------------------------------------------|--------------|-------------------|-------------|-----|
| Subjects (n)                                | 5,158        | 7,409             | 3,098       |     |
| Age at baseline (years)                     | 51.2 ± 10.5  | 51.2 ± 10.3       | 53.0 ± 10.4 | <0.0001 |
| Female                                      | 51.3         | 42.5              | 39.7        | <0.0001 |
| Race/ethnicity                              |              |                   |             | <0.0001 |
| American Indian or Pacific Islander         | 1.8          | 1.7               | 1.1         |     |
| Asian                                       | 10.7         | 10.0              | 8.3         |     |
| Black or African American                   | 7.6          | 7.0               | 7.4         |     |
| Hispanic                                    | 17.0         | 15.9              | 14.0        |     |
| Unknown                                     | 20.0         | 26.5              | 28.8        |     |
| White                                       | 43.0         | 39.0              | 40.4        |     |

10-year Framingham cardiovascular risk (%)†

| Group            | <10     | 10–19 | ≥20  |
|------------------|---------|-------|------|
|                  | 35.0    | 29.3  | 16.8 |

Microvascular diabetes complications††

| Group            | <10     | 10–19 | ≥20  |
|------------------|---------|-------|------|
|                  | 74.0    | 80.5  | 80.2 |

Data are means ± SD or percent unless otherwise indicated. *Median number of blood pressure measures per patient in this period was 4. **P values correspond to χ² test for categorical variables and ANOVA F test for continuous variables. †10-year cardiovascular FRS using total cholesterol, HDL cholesterol, SBP, age, sex, diabetes status (yes, no), smoking status (yes, no), and current hypertension medications (yes, no) (17). ††Modified version of the Diabetes Complications Severity Index (Young et al., 2008 [18]). The score is a count of common microvascular diabetes complications based on assigned ICD-9 diagnosis codes.

microvascular diabetes complications score, and site. A second model was constructed that included individual risk factors rather than the FRS.

**RESULTS**—Supplementary Fig. 2 shows inclusion and exclusion of study subjects as a flowchart. From 2003 to 2009, we identified 21,705 subjects with HT onset, of whom 18,842 were ages 30–74 years and had no cardiovascular comorbid condition and, therefore, were eligible for inclusion. Subjects were
excluded 1) if either of the two dates of data needed to define HT onset were not specified in the data tables (n = 94), 2) if fewer than two blood pressure measurements were done within 1 year of HT onset (n = 269), or 3) if enrollment ended within 1 year of HT onset (i.e., before the beginning of follow-up time for events) (n = 2,241). Final analytic sample size was 13,665 subjects. Baseline characteristics of patients with no blood pressure in the first year or with no follow-up time were similar to those included in the analysis. The median number of blood pressure measures used to classify blood pressure status in the follow-up period was four. Subjects with missing risk factor values (3.5%) had similar demographics and blood pressure measures at onset but a higher occurrence of major cardiovascular events (10.0 vs. 5.9 per 1,000 person-years).

Table 1 shows baseline and follow-up characteristics of study subjects classified by achieved blood pressure levels in the year after HT onset. Compared with patients with blood pressure <130/80 mmHg, patients with blood pressure ≥140/90 mmHg were older (53 vs. 51 years) and more likely to be male (39.7 vs. 51.3%) with higher 10-year FRS (23.1 vs. 16.5%), higher SBP (145.3 vs. 133.1 mmHg), and higher DBP (82.3 vs. 79.6 mmHg) at HT onset. Patients with blood pressure in the 130–139/80–89 mmHg range had risk factor patterns that resembled those of patients with blood pressure <130/80 mmHg.

In the first year after new-onset HT, 32.9% of subjects had mean blood pressure <130/80 mmHg and 80.2% had mean blood pressure <140/90 mmHg, leaving 19.8% with mean blood pressure ≥140/90 mmHg (Table 2). Blood pressure control (<130/80 mmHg) was similar in those initiating (31.5%) versus not initiating (33.9%) blood pressure–lowering medication. Rates of HT recognition and initiation of blood pressure–lowering medications increased, while rates of blood pressure control decreased with higher SBP levels at HT onset.

Age-adjusted rates of major cardiovascular events over a mean of 3.2 years (38 months) of follow-up are reported in Table 3. Lower SBP at HT onset and better blood pressure control status in the first year after HT onset were associated with fewer major cardiovascular events and fewer myocardial infarctions. However, HT recognition and treatment initiation in the first year were not associated with subsequent cardiovascular events.

Figure 1 presents the incidence RRs (95% CI) of the fully adjusted models for stroke, myocardial infarction, and all CVD events 1) comparing sustained HT blood pressure (≥140/90 mmHg) with blood pressure control (<140/90 mmHg) and 2) comparing sustained HT blood pressure (≥130/80 mmHg) with blood pressure control (<130/80 mmHg) after adjustment for baseline FRS (which includes age, sex, SBP, total cholesterol, HDL cholesterol, presence of diabetes, smoking status, and HT treatment), study site, and microvascular diabetes complications. Similar results were observed in separate models that adjusted for cardiovascular risk factors independently (SBP, HDL cholesterol, smoking, age, and sex) rather than adjusting for them in the aggregate using the FRS (data not shown). Subjects with sustained blood pressure ≥140/90 mmHg, compared with those with blood pressure <140/90 mmHg in the first year after HT onset, had higher likelihood of subsequent stroke (RR 1.25 [95% CI 0.85–1.82], P = 0.26), myocardial infarction (1.41 [1.01–1.96], P = 0.04), and any cardiovascular event (1.30 [1.01–1.69], P = 0.04). RRs were smaller and not statistically significant when comparing major cardiovascular event rates of those with blood pressure ≥130/80 mmHg versus those with blood pressure <130/80 mmHg.

We evaluated whether benefits of early blood pressure control vary significantly by baseline FRS or baseline presence of microvascular diabetes complications. In stratified analysis, the absolute number of events prevented by early blood pressure control was highest among those with FRS ≥20% (blood pressure <130/80 mmHg, 6.8/1,000 person-years, vs. blood pressure ≥140/90, 10.6/1,000 person-years) and lower among those with FRS <10% (3.4 vs. 5.8/1,000 person-years), with P = 0.14. Similar results were observed for microvascular diabetes complications, with no significant effect modification (P = 0.25).

CONCLUSIONS—In adults with diabetes, adequate blood pressure control in the first year after HT onset was associated with lower rates of any subsequent major cardiovascular event or myocardial infarction (but not with lower rates of stroke) in the 38-month mean follow-up period when analyzed in multivariable models. Compared with patients with mean blood pressure <140/90 mmHg, those with mean blood pressure ≥140/90 mmHg during the first year after HT onset had higher rates of major cardiovascular events (RR 1.30 [95% CI 1.01–1.69]; P = 0.04). These data support the hypothesis that adequate blood pressure control within a year of HT onset is an important clinical goal and suggest that achieving blood pressure <140/90 mmHg may confer most of the short-term benefits available from blood pressure lowering in such patients.

The observation that blood pressure control within the first year after HT onset may influence rates of some major cardiovascular events within 38 months was confirmed in the present study.

Table 2—Percent of subjects with hypertension recognition, treatment initiation, and categories of blood pressure in the year after hypertension onset in patients with diabetes

| SBP status at HT onset (mmHg) | Subjects (n) | With HT recognition in year after HT onset (%) | Blood pressure treatment initiation in year after HT onset (%) | Distribution according to categories of blood pressure in year after HT onset (mmHg)* |
|-----------------------------|-------------|--------------------------------|--------------------------------|-----------------------------------------------|
|                             |             |                              |                              | <130/80 | 130–139/80–89 | ≥140/90 |
| <130                        | 2,821       | 13.1                         | 25.1                         | 49.5   | 45.8         | 4.6     |
| 130–139                     | 6,643       | 21.2                         | 34.7                         | 38.1   | 52.5         | 9.4     |
| ≥140                        | 6,201       | 46.1                         | 53.6                         | 19.9   | 42.4         | 37.8     |
| Overall                     | 15,665      | 29.6                         | 40.5                         | 32.9   | 47.3         | 19.8     |

*Based on a median of four blood pressure readings in consecutive visits.
of mean follow-up suggests that insufficient attention has been devoted to the aggressive early management of blood pressure in patients with diabetes. The study subjects were relatively young at HT onset, with a mean age of 52 years, and important clinical effects detected after only 3 years of follow-up may become more pronounced over a longer follow-up period.

Degree of initial blood pressure elevation at HT onset, baseline FRS, and baseline severity of diabetes all predict greater likelihood of subsequent cardiovascular events in the next 3 years. Although the relative risk of cardiovascular events in relation to degree of HT control was similar across strata of FRS and microvascular diabetes complications, subgroups of diabetic patients with higher absolute baseline cardiovascular risks may benefit the most from early blood pressure control. Resolution of this issue is not possible in this study owing to limited power, so larger or longer studies are needed to fully resolve this clinical question.

Many patients with baseline SBP elevations of 130–139 mmHg reverted to normal levels of blood pressure within the first year without identification or recognition of their HT, and this may partly explain why insufficient attention has been devoted to the early management of blood pressure in these patients.

### Table 3

| Characteristic | Stroke (95% CI) | Myocardial infarction (95% CI) | Major cardiovascular events (95% CI) |
|----------------|----------------|---------------------------------|-------------------------------------|
| Overall rate   | 2.76 (2.34–3.26) | 3.37 (2.90–3.92) | 5.90 (5.26–6.62) |
| SBP at HT onset (mmHg) | | | |
| <130          | 3.16 (2.10–4.76) | 2.05 (1.24–3.40) | 5.10 (3.69–7.04) |
| 130–139       | 2.17 (1.62–2.90) | 2.22 (1.67–2.96) | 4.27 (3.47–5.25) |
| ≥140          | 2.54 (1.93–3.31) | 4.34 (3.27–5.71) | 6.94 (5.57–8.64) |
| P             | <0.33 | <0.0001 | 0.004 |
| Blood pressure control status in year after date of HT onset (mmHg) | | | |
| <130/80       | 2.11 (1.51–2.94) | 2.76 (2.06–3.71) | 4.75 (3.80–5.95) |
| 130–139/80–89 | 2.50 (1.93–3.23) | 2.76 (2.16–3.52) | 5.02 (4.19–6.02) |
| ≥140/90       | 3.01 (2.17–4.19) | 4.32 (3.27–5.71) | 6.94 (5.57–8.64) |
| P             | 0.31 | 0.03 | 0.03 |
| Hypertension treatment initiation in year after HT onset | | | |
| Yes           | 2.62 (2.01–3.42) | 3.42 (2.70–4.32) | 5.77 (4.82–6.92) |
| No            | 2.40 (1.90–3.03) | 2.89 (2.34–3.51) | 5.07 (4.32–5.96) |
| P             | 0.60 | 0.28 | 0.27 |
| Hypertension recognition in year after HT onset | | | |
| Yes           | 2.54 (1.87–3.45) | 3.26 (2.48–4.28) | 5.46 (4.42–6.73) |
| No            | 2.46 (1.98–3.05) | 3.03 (2.50–3.68) | 5.31 (4.58–6.15) |
| P             | 0.86 | 0.83 | 0.66 |

Data are RRs (95% CI). *Major cardiovascular events include myocardial infarction and hemorrhagic and thrombotic stroke; RRs were calculated using Poisson regression model with age centered at the mean of the population. P values correspond to type 3 likelihood ratio statistics.

### Figure 1

**A** Event RR (95% CI) 130/80+ vs. <130/80

| CV  | 1.19 (0.92–1.55), 0.19 |
| MI  | 1.18 (0.84–1.66), 0.35 |
| Stroke | 1.28 (0.87–1.89), 0.21 |

**B** Event RR (95% CI) 140/90+ vs. <140/90

| CV  | 1.30 (1.01–1.69), 0.04 |
| MI  | 1.41 (1.01–1.96), 0.04 |
| Stroke | 1.25 (0.85–1.82), 0.26 |

**Figure 1**—Adjusted incidence RRs (95% CI) for stroke, myocardial infarction (MI), and other major cardiovascular (CV) events estimated based on mean level of blood pressure control in the year after hypertension onset. Categories of blood pressure control in the year after hypertension onset include the following: above versus below 130/80 mmHg (A) and above versus below 140/90 mmHg (B). Major cardiovascular events are defined as myocardial infarction, hemorrhagic stroke, or thrombotic stroke in the mean 38-month follow-up period. Poisson regression models included FRS, microvascular diabetes complications, and site.
treatment. This suggests that JNC-7 diagnostic criteria for HT for those with diabetes (two consecutive blood pressure measurements of $\geq 130/80$ mmHg on different days) may identify many patients whose office blood pressure elevations reflect transiently elevated blood pressure related to cooccurrence of a time-limited medical or psychological condition such as pain or stress.

Several factors constrain the interpretation of our data. First, the observational study design precludes causal inference. Second, generalizability may be limited because study subjects were insured patients receiving care at only three health systems. Third, routine blood pressure measurements obtained at community clinics are subject to rounding errors and other sources of inaccuracy (19,20). However, study sites used defined blood pressure measurement protocols and, periodically, trained nursing staff in blood pressure measurement. In addition, we classified onset of HT and HT control status based on multiple blood pressure readings to attenuate misclassification related to measurement error. Fourth, our ascertainment of incident cardiovascular events may be incomplete. However, incomplete ascertainment of myocardial infarction and stroke is likely to be minimal when both clinical and claims data are available, as they were in this study.

In summary, among adults with diabetes, control of blood pressure to $<140/90$ mmHg within 1 year of HT onset significantly reduced the likelihood of major cardiovascular events within the next 3 years. Prompt identification and control of HT in patients with diabetes may provide very important short-term clinical benefits.

Acknowledgments — This project was funded under contract no. HS0290-2005-00331 from the Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services (DHHS), as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program.

No potential conflicts of interest relevant to this article were reported.

P.J.O. wrote the manuscript and obtained funding. G.V.-B. analyzed data, drafted RESEARCH DESIGN AND METHODS and RESULTS, and edited and reviewed the manuscript. J.A.S., E.D.P., J.R.D., and K.L.M. reviewed and edited the manuscript. N.K.T. analyzed data. D.J.M. reviewed and edited the manuscript and obtained funding. P.J.O. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References
1. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:713–720
2. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565–1576
3. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.; Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677–684
4. Hansson L, Zanchetti A, Carruthers SG, et al.; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755–1762
5. Zanchetti A, Hansson L, Clement D, et al.; HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003;21:797–804
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713
7. Schrier RW, Estacio RO, Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) Trial. Diabetologia 1996;39:1646–1654
8. Estacio RO, Jeffers BW, Liatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645–652
9. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl. 2):B54–B64
10. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61–68
11. Cushman WC, Evans GW, Byington RP, et al.; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575–1585
12. Curb JD, Pressel SL, Cutler JA, et al.; Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886–1892
13. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–840
14. Selby JV, Lee J, Swain BE, et al. Trends in time to confirmation and recognition of new-onset hypertension, 2002–2006. Hypertension 2010;56:605–611
15. Maddox TM, Ross C, Tavel HM, et al. Blood pressure trajectories and associations with treatment intensification, medication adherence, and outcomes among newly diagnosed coronary artery disease patients. Circ Cardiovasc Qual Outcomes 2010;3:347–357
16. O’Connor PJ, Rush WA, Promk NP, Cherney LM. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Manag Care 1998;4:335–342
17. Young BA, Lim E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15–23
18. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753
19. Verberk WJ, Kroon AA, Thien T, et al. Prevalence of the white-coat effect at multiple visits before and during treatment. J Hypertens 2006;24:2357–2363
20. Thavarajah S, White WB, Mansoor GA. Terminal digit bias in a specialty hypertension faculty practice. J Hum Hypertens 2003;17:819–822